| Date | Title | Description |
| 01.03.2024 | Replicate Bioscience to Participate in Upcoming Investor and... | SAN DIEGO, March 1, 2024 (PRNewswire) -- Replicate Bioscience, a clinical-stage company pioneering n... |
| 14.02.2024 | Replicate Bioscience Announces Positive Initial Clinical Res... | Replicate's srRNA vaccine elicited a protective immune response that met the WHO threshold for prote... |
| 29.01.2024 | Ascidian Therapeutics Announces First-Ever IND for an RNA Ex... | ACDN-01 is the first RNA exon editor to enter clinical development and the only clinical-stage thera... |
| 29.01.2024 | Ascidian Therapeutics Announces First-Ever IND for an RNA Ex... | ACDN-01 is the first RNA exon editor to enter clinical development and the only clinical-stage thera... |
| 25.01.2024 | First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s... | Preliminary Phase 2 data in melanoma, renal cell carcinoma anticipated to be presented by mid-2024
... |
| 25.01.2024 | First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s... | - |
| 05.01.2024 | Novel Compound Protects Against Infection by Virus that Caus... | Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of... |
| 05.01.2024 | Novel Compound Protects Against Infection by Virus that Caus... | Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of... |
| 18.12.2023 | Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase... | Phase 2 study follows on positive Phase 1 data showing early anti-tumor activity in heavily pre-trea... |
| 18.12.2023 | Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase... | Phase 2 study follows on positive Phase 1 data showing early anti-tumor activity in heavily pre-trea... |
| 14.12.2023 | Apple Tree Partners Unveils Deep Apple Therapeutics to Drama... | Conducting entirely virtual screens of multi-billion molecule virtual libraries, Deep Apple can quic... |
| 14.12.2023 | Apple Tree Partners Unveils Deep Apple Therapeutics to Drama... | Conducting entirely virtual screens of multi-billion molecule virtual libraries, Deep Apple can quic... |
| 07.12.2023 | Marengo Therapeutics and Kings College London Announce Publi... | Antibodies to germline-encoded TCR β-chain alleles drive T cells to distinct memory-like effector st... |
| 06.12.2023 | Marengo Therapeutics Announces Publication Describing STAR06... | Marengo's first pan-tumor Vβ T cell activator, STAR0602, expands Vβ6 T cells that drive potent, sing... |
| 13.11.2023 | Nereid Therapeutics Appoints Michael Kauffman as CEO | Seasoned industry executive with decades of success in drug discovery, development, regulatory appro... |
| 13.11.2023 | Nereid Therapeutics Appoints Michael Kauffman as CEO | Seasoned industry executive with decades of success in drug discovery, development, regulatory appro... |
| 08.11.2023 | Ascidian Therapeutics Raises $40 Million in Series A Extensi... | Funds from ATP will support the progress of Ascidian’s lead program in ABCA4 retinopathies, includin... |
| 08.11.2023 | Ascidian Therapeutics Raises $40 Million in Series A Extensi... | Funds from ATP will support the progress of Ascidian’s lead program in ABCA4 retinopathies, includin... |
| 06.11.2023 | Galvanize Therapeutics Announces Promising Data on the Aliya... | SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed ... |
| 06.11.2023 | Galvanize Therapeutics Announces Promising Data on the Aliya... | SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed ... |
| 03.11.2023 | New Phase 1 Dose Escalation Data Show Well-Tolerated Safety ... | - |
| 03.11.2023 | New Phase 1 Dose Escalation Data Show Well-Tolerated Safety ... | Preliminary evidence of anti-tumor activity observed in heavily pre-treated patients, including thos... |
| 14.10.2023 | New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscienc... | - |
| 14.10.2023 | New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscienc... | Interim data from an ongoing trial support overall mechanism of action of AU-007, a computationally ... |
| 04.10.2023 | Aulos Bioscience to Present Encouraging Pharmacodynamic Data... | - |
| 04.10.2023 | Aulos Bioscience to Present Encouraging Pharmacodynamic Data... | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutio... |
| 27.09.2023 | Aulos Bioscience Announces Presentation of Updated Safety an... | - |
| 27.09.2023 | Aulos Bioscience Announces Presentation of Updated Safety an... | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutio... |
| 20.09.2023 | Galvanize Therapeutics Begins U.S. Clinical Study Using Aliy... | First patient treated in the U.S. with Aliya PEF delivered via an endobronchial approach with roboti... |
| 20.09.2023 | Galvanize Therapeutics Begins U.S. Clinical Study Using Aliy... | First patient treated in the U.S. with Aliya PEF delivered via an endobronchial approach with roboti... |
| 12.09.2023 | Nine Square Therapeutics Awarded $4.5 Million Grant from The... | - |
| 12.09.2023 | Replicate Bioscience Initiates a Phase 1 Trial of its Next-G... | SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering ... |
| 12.09.2023 | Replicate Bioscience Initiates a Phase 1 Trial of its Next-G... | SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering ... |
| 12.09.2023 | Nine Square Therapeutics Awarded $4.5 Million Grant from The... | Nine Square is building a diversified portfolio of first-in-class drug candidates for genetically v... |
| 05.09.2023 | BRIXADI® (buprenorphine) Extended-Release Injection for Subc... | BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution pr... |
| 05.09.2023 | BRIXADI® (buprenorphine) Extended-Release Injection for Subc... | BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution pr... |
| 01.08.2023 | Aulos Bioscience Raises $20 Million in Series A Extension Fi... | Funds from ATP will continue to sustain the progress of Aulos’ novel IL-2 therapeutic AU-007 through... |
| 01.08.2023 | Aulos Bioscience Raises $20 Million in Series A Extension Fi... | - |
| 11.07.2023 | Apple Tree Partners Recruits Noted Biotech Entrepreneur and ... | Jacobson, an eminent research scientist working across disciplines including computational biophysic... |
| 11.07.2023 | Apple Tree Partners Recruits Noted Biotech Entrepreneur and ... | Jacobson, an eminent research scientist working across disciplines including computational biophysic... |
| 10.07.2023 | Replicate Bioscience Appoints Rachael Lester as Chief Busine... | Biopharma executive with more than 20 years of global corporate, business development, and commercia... |
| 10.07.2023 | Replicate Bioscience Appoints Rachael Lester as Chief Busine... | Biopharma executive with more than 20 years of global corporate, business development, and commercia... |
| 27.06.2023 | Intergalactic Therapeutics Announces Positive Results for It... | Data from IG-002, Intergalactic's lead program, demonstrate persistent ABCA4 expression in non-human... |
| 27.06.2023 | Intergalactic Therapeutics Announces Positive Results for It... | Data from IG-002, Intergalactic's lead program, demonstrate persistent ABCA4 expression in non-human... |
| 19.06.2023 | Galvanize Therapeutics Completes Enrollment in Pivotal Trial... | REDWOOD CITY, Calif., June 19, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in develo... |
| 19.06.2023 | Galvanize Therapeutics Completes Enrollment in Pivotal Trial... | REDWOOD CITY, Calif., June 19, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in develo... |
| 12.06.2023 | Chinook Therapeutics Enters into Agreement to be Acquired by... | Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional... |
| 12.06.2023 | Chinook Therapeutics Enters into Agreement to be Acquired by... | Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional... |
| 05.06.2023 | Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Saf... | Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in live... |
| 05.06.2023 | Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Saf... | Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in live... |
| 30.05.2023 | Galvanize Announces License Agreement and Partnership with E... | License will maximize the availability of Pulsed Electric Field therapies for the population
Energe... |
| 30.05.2023 | Galvanize Announces License Agreement and Partnership with E... | License will maximize the availability of Pulsed Electric Field therapies for the population |
| 25.05.2023 | Interim Results From Phase 1/2 Clinical Trial in Solid Tumor... | New data in ASCO 2023 abstract show continued trend in decreasing Tregs and eosinophils, bolstering ... |
| 25.05.2023 | Interim Results From Phase 1/2 Clinical Trial in Solid Tumor... | New data in ASCO 2023 abstract show continued trend in decreasing Tregs and eosinophils, bolstering ... |
| 23.05.2023 | FDA News Release: FDA Approves New Buprenorphine Treatment O... | Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injec... |
| 23.05.2023 | Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcuta... | BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly dose... |
| 23.05.2023 | Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcuta... | BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly dose... |
| 23.05.2023 | FDA News Release: FDA Approves New Buprenorphine Treatment O... | Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injec... |
| 16.05.2023 | Intergalactic Therapeutics to Host Virtual KOL Investor Even... | CAMBRIDGE, Mass., May 16, 2023 /PRNewswire/ -- Intergalactic Therapeutics, a company focused on tran... |
| 16.05.2023 | Intergalactic Therapeutics to Host Virtual KOL Investor Even... | CAMBRIDGE, Mass., May 16, 2023 /PRNewswire/ -- Intergalactic Therapeutics, a company focused on tran... |
| 11.05.2023 | Intergalactic Therapeutics to Present Preclinical Data Highl... | Lead program, IG-002 targeting ABCA4 retinopathies demonstrated long-term, persistent protein expres... |
| 11.05.2023 | Intergalactic Therapeutics to Present Preclinical Data Highl... | Lead program, IG-002 targeting ABCA4 retinopathies demonstrated long-term, persistent protein expres... |
| 09.05.2023 | Ascidian Therapeutics to Present New Data From Its Lead Prog... | Latest six-month data from lead ABCA4 program demonstrate efficient and durable production of full-l... |
| 09.05.2023 | Ascidian Therapeutics to Present New Data From Its Lead Prog... | Latest six-month data from lead ABCA4 program demonstrate efficient and durable production of full-l... |
| 01.05.2023 | With $75 Million from Apple Tree Partners, Initial Therapeut... | Initial was created to take on undruggable disease-causing proteins by discriminately intercepting t... |
| 01.05.2023 | With $75 Million from Apple Tree Partners, Initial Therapeut... | Initial was created to take on undruggable disease-causing proteins by discriminately intercepting t... |
| 20.04.2023 | Intergalactic Therapeutics to Present Updated Data From Its ... | Lead program, IG-002 targeting ABCA4 retinopathies, demonstrates durable 12-month expression of huma... |
| 20.04.2023 | Intergalactic Therapeutics to Present Updated Data From Its ... | Lead program, IG-002 targeting ABCA4 retinopathies, demonstrates durable 12-month expression of huma... |
| 19.04.2023 | Replicate Bioscience Presents Preclinical srRNA Data at the ... | Preclinical studies provide proof-of-concept for Replicate's novel srRNA platform and programs |
| 19.04.2023 | Replicate Bioscience Presents Preclinical srRNA Data at the ... | Preclinical studies provide proof-of-concept for Replicate's novel srRNA platform and programs
RBI-... |
| 18.04.2023 | Ascidian Therapeutics to Present Data From Its Lead Program ... | New six-month durability data from lead ABCA4 program demonstrate the most efficient and durable RNA... |
| 18.04.2023 | Ascidian Therapeutics to Present Data From Its Lead Program ... | New six-month durability data from lead ABCA4 program demonstrate the most efficient and durable RNA... |
| 11.04.2023 | Ascidian Therapeutics Announces Three Key Development Team A... | Leadership appointments come as Ascidian's lead program targeting ABCA4 retinopathies, including Sta... |
| 11.04.2023 | Ascidian Therapeutics Announces Three Key Development Team A... | Leadership appointments come as Ascidian's lead program targeting ABCA4 retinopathies, including Sta... |
| 22.03.2023 | Marengo Therapeutics to Present a Late-Breaking Abstract at ... | CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering no... |
| 22.03.2023 | Marengo Therapeutics to Present a Late-Breaking Abstract at ... | CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering no... |
| 20.03.2023 | Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief ... | BOSTON, March 20, 2023 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company focused on tre... |
| 20.03.2023 | Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief ... | BOSTON, March 20, 2023 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company focused on tre... |
| 15.03.2023 | Intergalactic Therapeutics Announces Positive Preclinical Re... | Data for IG-002 show for the first time that a single subretinal administration of a DNA payload enc... |
| 15.03.2023 | Intergalactic Therapeutics Announces Positive Preclinical Re... | Data for IG-002 show for the first time that a single subretinal administration of a DNA payload enc... |
| 14.03.2023 | Replicate Bioscience Shares New Preclinical srRNA Data at Am... | Poster presentations provide data on Replicate's lead immuno-oncology candidate, RBI-1000, in target... |
| 14.03.2023 | Replicate Bioscience Shares New Preclinical srRNA Data at Am... | Poster presentations provide data on Replicate's lead immuno-oncology candidate, RBI-1000, in target... |
| 07.03.2023 | New Interventional Oncology Data Show Potential for Aliya™ P... | Galvanize Therapeutics data presented at SIR 2023 include PEF safety and feasibility results in pati... |
| 07.03.2023 | New Interventional Oncology Data Show Potential for Aliya™ P... | Galvanize Therapeutics data presented at SIR 2023 include PEF safety and feasibility results in pati... |
| 01.03.2023 | Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Me... | CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering nov... |
| 01.03.2023 | Galvanize Therapeutics Announces First Human Use of QuickSho... | REDWOOD CITY, Calif., March 1, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc. today announced the... |
| 01.03.2023 | Galvanize Therapeutics Announces First Human Use of QuickSho... | REDWOOD CITY, Calif., March 1, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc. today announced the... |
| 01.03.2023 | Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Me... | CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering nov... |
| 17.02.2023 | Gene editing: DNA versus RNA (Drug Discovery News) | Treating disease is often a matter of restoring the function of a specific protein, process, or path... |
| 17.02.2023 | Gene editing: DNA versus RNA (Drug Discovery News) | Researchers correcting the genetic causes of disease at the DNA or RNA level make their cases.
Trea... |
| 01.02.2023 | First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Cli... | - |
| 01.02.2023 | First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Cli... | Dosing marks first time a computationally designed monoclonal antibody enters human trial in the U.S... |
| 27.01.2023 | Marengo Therapeutics Announces First Patient Dosed in Phase ... | START-001 study leverages a biomarker-enriched tissue-agnostic approach to evaluate the activity of ... |
| 27.01.2023 | Marengo Therapeutics Announces First Patient Dosed in Phase ... | START-001 study leverages a biomarker-enriched tissue-agnostic approach to evaluate the activity of ... |
| 17.01.2023 | Why I invited investors into my lab: Adendra Therapeutics co... | In December 2021, Apple Tree Partners (ATP), a leader in life sciences venture capital, announced th... |
| 17.01.2023 | Why I invited investors into my lab: Adendra Therapeutics co... | In December 2021, Apple Tree Partners (ATP), a leader in life sciences venture capital, announced th... |
| 09.01.2023 | ATP and NYU Langone Health Launch Aethon Therapeutics to Era... | Aethon’s HapImmune™ platform, described in a recent publication in the journal Cancer Discovery, uni... |
| 09.01.2023 | ATP and NYU Langone Health Launch Aethon Therapeutics to Era... | |
| 06.01.2023 | Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D.,... | BOSTON, Jan. 6, 2023 /PRNewswire/ -- Intergalactic Therapeutics, a company focused on transforming m... |
| 06.01.2023 | Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D.,... | BOSTON, Jan. 6, 2023 /PRNewswire/ -- Intergalactic Therapeutics, a company focused on transforming m... |
